Back to results
US 9,068,228 B2Granted
Method for screening ameliorants of dry skin caused by atopic dermatitis using bleomycin hydrolase activity as indicator
AssigneeShiseido Company, Ltd.
InventorsToshihiko Hibino, Yayoi Kamata, Mami Yamamoto
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for screening and evaluating ameliorants of dry skin caused by atopic dermatitis, comprising: evaluating a candidate drug as being an ameliorant of dry skin caused by atopic dermatitis in the case the candidate drug significantly increases expression and/or activity of bleomycin hydrolase in comparison with a control drug.
Claims1
A method for diagnosing predisposition to dry skin caused by atopic dermatitis in human subject, comprising:
- diagnosing a tendency towards dry skin caused by atopic dermatitis in the case expression and/or activity of bleomycin hydrolase in skin tissue is significantly decreased in comparison with that of control skin in human cells, while diagnosing the absence of a tendency towards dry skin caused by atopic dermatitis if it is equal to or greater than that of the control skin in human cells, wherein the expression and/or activity is judged to be significantly decreased in the case the transcription activity of a gene that encodes bleomycin hydrolase is significantly decreased in comparison with that of a control, and wherein the transcription activity is judged to be decreased in the case binding activity of transcription factors IRF-1, IRF-2, MZF-1, Sp-1 and/or GATA-1 is significantly decreased in comparison with that of a control.
Dependencies are inferred from the claim text.